Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE: Vericiguat in Cardiac Surgery
NCT05812755Phase 4Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Vericiguat oral suspension (Formulation 4) in acute kidney injury (AKI), traumatic brain injury (TBI) and endothelial dysfunction (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Brachial artery flow-mediated dilation, Ex vivo vascular relaxation and 2 more. Started May 2023; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
acute kidney injury (AKI)traumatic brain injury (TBI)endothelial dysfunction
Beyond the preview
Go deeper on NCT05812755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812755.